Implantation of a new phakic IOL may be as safe, effective and predictable as previous IOL models to correct myopia, according to a study.The prospective nonrandomized clinical study analyzed 121 eyes of 68 patients after implantation of the V4b model …
Geographic Atrophy: Clinical Impact and Emerging Treatments
Geographic atrophy remains an important cause of permanent vision loss despite historic progress made in managing vitreoretinal diseases over the past decade. Fortunately, our understanding of age-related macular degeneration pathophysiology has reache…
New test can help measure vital aspects of retinal health
New research published in the February 2015 issue of The FASEB Journal details a test developed using mice that can help measure two important aspects of retinal health–the function of retinal blood vessels and light-detecting cells. This approach ope…
Obama proposes new agency to consolidate US food safety system
In his Fiscal Year 2016 Budget, President Barack Obama requested creation of a new agency under the HHS that would consolidate food safety components of the FDA and the U.S. Food Safety and Inspection Service.The new stand-alone agency would operate in…
Abbott reports $20.2 billion in 2014 net sales
Abbott reported net sales of $20.2 billion for 2014, a 3% increase from 2013, according to a press release. Yearly net earnings totaled $2.3 billion compared with $2.6 billion the previous year, a decrease of 11.3%.
Eylea for macular edema secondary to CRVO, BRVO recommended for approval in EU
The European Committee for Medicinal Products for Human Use recommended the approval of Eylea for the treatment of visual impairment due to macular edema secondary to central or branch retinal vein occlusion, according to a press release from Regeneron…